uniQure price to sales ratio QURE
Market value divided by revenue over the last twelve months, since 2017.
- Today, Nov 2, 2026
- 85.3×
- 9-year median
- 24.4×
- Against its 9-year history
- 80th
- percentile: 0 is its lowest day, 100 its highest
- 9-year range
- 1.2× to 199×
- Peer median
- 2.0×
uniQure's price to sales ratio is 85.3× as of Nov 2, 2026.
That is above its 9-year median of 24.4×, higher than on 80% of days in the last 9 years.
Over that time it ranged from 1.2× in May 2022 to 199× in Mar 2019.
The median for 10 large drugmakers of a similar size is 2.0×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 85.3× | 55.4× | 181× |
| 2025 | 98.1× | 17.8× | 118× |
| 2024 | 29.8× | 2.3× | 29.8× |
| 2023 | 2.9× | 2.4× | 17.6× |
| 2022 | 17.3× | 1.2× | 20.5× |
| 2021 | 1.9× | 1.9× | 43.8× |
| 2020 | n/m a value too high to mean anything | ||
| 2019 | 194× | 85.6× | 199× |
| 2018 | 81.9× | 27.6× | 139× |
| 2017 | 30.7× | 23.6× | 30.7× |
Against its peers
Companies in Drug Manufacturers - General nearest uniQure's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| QUREuniQure | 85.3× |
| PAHCPhibro Animal Health | 1.0× |
| ANIPANI Pharmaceuticals | 1.7× |
| PCRXPacira BioSciences | 1.9× |
| ANABAnaptysbio | n/m |
| OMEROmeros | n/m |
| HRMYHarmony Biosciences | 2.3× |
| AMPHAmphastar Pharmaceuticals | 1.6× |
| PBHPrestige Consumer Healthcare | 2.1× |
| NRIXNurix Therapeutics | 4.0× |
| ABUSArbutus Biopharma | 4.4× |
| Peer median | 2.0× |
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on uniQure
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.